Long-Acting IL-7 (NT-I7) as an Immune Reconstitution Strategy in PML: Immunological and Clinical Outcomes from a Pilot Study (LS1.002)

Yair Mina; Sara Zahraeifard; Busranur Agac; Poorva Jain; Anita Fletcher; Jemima Akinsanya; Donghoon Choi; Soung-Min Lee; Sun‐Kyoung Im; Alexandra Wolfarth; Maria Chiara Monaco; Maryam Sharifian Dorche; Mauricio Campillay; Milo Taylor; Gina Norato; Govind Nair; Daniel Reich; Irene Cortese

doi:10.1212/wnl.0000000000217896

Key Points

This pilot study aims to assess the safety, tolerability, and immunologic effects of NT-I7 for immune reconstitution in PML-related lymphopenia.
Evaluated safety and tolerability of NT-I7 in patients with lymphopenia due to PML.
Monitored immunologic effects post-administration of recombinant interleukin-7 (rhIL-7-hyFc).
NT-I7 showed improved immunologic outcomes in patients with PML-associated lymphopenia.
Safety and tolerability were maintained without significant adverse effects.

Implication

Pilot study evaluates immunologic effects of NT-I7 in patients with lymphopenia due to PML, suggesting potential benefits.

Abstract

To evaluate the safety, tolerability, and immunologic effects of NT-I7, a long-acting recombinant interleukin-7 (rhIL-7-hyFc), as an immune-reconstitution strategy for lymphopenia in patients with progressive multifocal leukoencephalopathy (PML).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mina et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0563fd https://doi.org/10.1212/wnl.0000000000217896

View Full Paper

Ask AI

Bookmark

Share

Long-Acting IL-7 (NT-I7) as an Immune Reconstitution Strategy in PML: Immunological and Clinical Outcomes from a Pilot Study (LS1.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Long-Acting IL-7 (NT-I7) as an Immune Reconstitution Strategy in PML: Immunological and Clinical Outcomes from a Pilot Study (LS1.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading